David I. Quinn

28.0k total citations · 4 hit papers
420 papers, 14.1k citations indexed

About

David I. Quinn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, David I. Quinn has authored 420 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 259 papers in Pulmonary and Respiratory Medicine, 204 papers in Oncology and 125 papers in Surgery. Recurrent topics in David I. Quinn's work include Prostate Cancer Treatment and Research (156 papers), Bladder and Urothelial Cancer Treatments (94 papers) and Cancer Immunotherapy and Biomarkers (86 papers). David I. Quinn is often cited by papers focused on Prostate Cancer Treatment and Research (156 papers), Bladder and Urothelial Cancer Treatments (94 papers) and Cancer Immunotherapy and Biomarkers (86 papers). David I. Quinn collaborates with scholars based in United States, Australia and France. David I. Quinn's co-authors include Tanya B. Dorff, Nicholas J. Vogelzang, Daniel P. Petrylak, Toni K. Choueiri, Dean F. Bajorin, Joaquim Bellmunt, Cora N. Sternberg, David J. Vaughn, Andrea Necchi and Robert L. Sutherland and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

David I. Quinn

405 papers receiving 13.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2017 2.4k citations Joaquim Bellmunt, Ronald de Wit et al. New England Journal of Medicine profile →
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

2019 306 citations Yves Fradet, Joaquim Bellmunt et al. profile →
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

2021 175 citations Daniel P. Petrylak, Peter H. O’Donnell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David I. Quinn United States	59	5.8k	4.8k	4.5k	4.0k	2.3k	420	14.1k
Yoshiharu Sakai Japan	61	5.4k 0.9×	3.0k 0.6×	4.1k 0.9×	3.2k 0.8×	1.6k 0.7×	409	11.8k
Roy M. Bremnes Norway	59	6.3k 1.1×	4.2k 0.9×	2.5k 0.5×	4.4k 1.1×	2.4k 1.0×	229	13.0k
Mototsugu Oya Japan	50	3.2k 0.6×	4.5k 0.9×	3.4k 0.8×	3.8k 1.0×	1.9k 0.8×	622	11.2k
Jiafu Ji China	53	4.3k 0.7×	5.3k 1.1×	3.0k 0.7×	5.5k 1.4×	2.5k 1.1×	486	14.4k
Guru Sonpavde United States	53	6.9k 1.2×	5.1k 1.0×	6.5k 1.4×	3.3k 0.8×	2.3k 1.0×	628	15.1k
Sun Young Rha South Korea	63	7.8k 1.3×	8.9k 1.8×	3.4k 0.7×	6.3k 1.6×	3.2k 1.4×	710	17.9k
Marianna Zahurak United States	69	6.8k 1.2×	5.0k 1.0×	5.7k 1.3×	3.5k 0.9×	2.1k 0.9×	221	16.8k
Dan Theodorescu United States	69	3.6k 0.6×	3.1k 0.6×	3.8k 0.9×	7.5k 1.9×	2.8k 1.2×	335	14.6k
Daniele Santini Italy	63	8.8k 1.5×	4.1k 0.9×	2.5k 0.6×	4.0k 1.0×	2.6k 1.1×	618	15.1k
Nizar M. Tannir United States	61	4.7k 0.8×	7.8k 1.6×	2.2k 0.5×	6.0k 1.5×	3.6k 1.6×	487	12.8k

Countries citing papers authored by David I. Quinn

Since Specialization

Citations

This map shows the geographic impact of David I. Quinn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David I. Quinn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David I. Quinn more than expected).

Fields of papers citing papers by David I. Quinn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David I. Quinn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David I. Quinn. The network helps show where David I. Quinn may publish in the future.

Co-authorship network of co-authors of David I. Quinn

This figure shows the co-authorship network connecting the top 25 collaborators of David I. Quinn. A scholar is included among the top collaborators of David I. Quinn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David I. Quinn. David I. Quinn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lancelotta, Rafael, David I. Quinn, Natalie Gukasyan, et al.. (2025). Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study. Journal of Psychoactive Drugs. 1–14. 2 indexed citations

Gitlitz, Barbara J., Vinay Duddalwar, Kevin G. King, et al.. (2024). Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma. Oncotarget. 15(1). 444–458.

Sayegh, Nicolas, Umang Swami, Yeonjung Jo, et al.. (2023). Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer. JAMA Network Open. 6(8). e2326546–e2326546. 5 indexed citations

Sekino, Yohei, Hongtao Li, Guanghou Fu, et al.. (2023). SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer. Cancer Research. 83(22). 3813–3826. 11 indexed citations

Antonarakis, Emmanuel S., Sumit K. Subudhi, Christopher Pieczonka, et al.. (2023). Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research. 29(13). 2426–2434. 10 indexed citations

Buckley, Jonathan D., Dejerianne Ostrow, Bino Varghese, et al.. (2022). Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. International Journal of Molecular Sciences. 23(5). 2571–2571. 12 indexed citations

Agarwal, Neeraj, Catherine M. Tangen, Maha Hussain, et al.. (2022). Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Journal of Clinical Oncology. 40(28). 3301–3309. 30 indexed citations

Damrauer, Jeffrey S., Jeffrey A. Klomp, Mi Zhou, et al.. (2022). Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature Communications. 13(1). 6658–6658. 27 indexed citations

Xu, Yucheng, Eric S. C. Kwok, Tanya B. Dorff, et al.. (2020). Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. International Journal of Cancer. 146(10). 2845–2854. 8 indexed citations

10.

Liu, Ren, et al.. (2020). Tetraspanin18 regulates angiogenesis through VEGFR2 and Notch pathways. Biology Open. 10(2). 13 indexed citations

11.

Ballas, Leslie K., Siamak Daneshmand, Anne Schuckman, et al.. (2020). Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. Clinical Genitourinary Cancer. 18(4). e473–e477.

12.

Gross, Mitchell E., David B. Agus, Tanya B. Dorff, et al.. (2020). Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 24(1). 61–68. 42 indexed citations

13.

Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology. 38(10). 1041–1049. 223 indexed citations breakdown →

14.

Antonarakis, Emmanuel S., Eric J. Small, Daniel P. Petrylak, et al.. (2018). Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research. 24(19). 4662–4671. 26 indexed citations

15.

Пили, Роберто, David I. Quinn, Hans J. Hammers, et al.. (2017). Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clinical Cancer Research. 23(23). 7199–7208. 76 indexed citations

16.

Dorff, Tanya B., Jeff Longmate, Sumanta K. Pal, et al.. (2017). Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. Cancer. 123(23). 4566–4573. 36 indexed citations

17.

Bellmunt, Joaquim, Ronald de Wit, David J. Vaughn, et al.. (2017). Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine. 376(11). 1015–1026. 2374 indexed citations breakdown →

18.

Liu, Stephen V., Denice Tsao‐Wei, Shigang Xiong, et al.. (2014). Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clinical Cancer Research. 20(24). 6277–6283. 37 indexed citations

19.

Ell, Kathleen, et al.. (2008). Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With Cancer. Journal of Clinical Oncology. 26(27). 4488–4496. 201 indexed citations

20.

Lara, Primo N., David I. Quinn, Kim Margolin, et al.. (2003). SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.. PubMed. 9(13). 4772–81. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact